Arcus Biosciences (RCUS) Total Liabilities (2017 - 2026)

Arcus Biosciences' Total Liabilities history runs 10 years deep, the most recent figure standing at $997.0 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 16.92% year-over-year to $997.0 million in Q1 2026; TTM through Mar 2026 was $997.0 million, a 16.92% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 0.96% from the prior year.
• Total Liabilities retreated to $997.0 million in Q1 2026 per RCUS's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $1.3 billion in Q4 2022 and bottomed at $695.1 million in Q3 2022.
• The 5-year median for Total Liabilities is $1.2 billion (2024), against an average of $1.1 billion.
• Across the five-year window, Total Liabilities jumped 176.27% in 2022 and declined 25.08% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $1.3 billion in 2022, then declined by 15.77% to $1.1 billion in 2023, then gained by 5.02% to $1.2 billion in 2024, then fell by 0.96% to $1.1 billion in 2025, then dropped by 12.47% to $997.0 million in 2026.
• Per Business Quant, the three latest RCUS Total Liabilities figures stand at $997.0 million (Q1 2026), $1.1 billion (Q4 2025), and $974.0 million (Q3 2025).